Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies

Gene Therapy

Volumn 14, Issue 4, 2007, Pages 324-333

  Ong, H T ^a   Hasegawa, K ^a   Dietz, A B ^a   Russell, S J ^a   Peng, K W ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; INDIUM 111; LUCIFERASE; ONCOLYTIC PARAMYXOVIRUS; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BIOLUMINESCENCE; CELL BASED GENE THERAPY; CELL FUSION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MEASLES VIRUS; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; T LYMPHOCYTE; TUMOR XENOGRAFT; VIRUS TRANSMISSION;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; GAMMA CAMERAS; GREEN FLUORESCENT PROTEINS; HUMANS; INDIUM RADIOISOTOPES; INJECTIONS; LUCIFERASES; LYMPHOCYTE ACTIVATION; MEASLES; MEASLES VACCINE; MEASLES VIRUS; MICE; MICE, SCID; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; NEUTRALIZATION TESTS; ONCOLYTIC VIROTHERAPY; RADIOPHARMACEUTICALS; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS;

MEASLES VIRUS; MUS;

EID: 33846900675     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302880     Document Type: Article

References (37)

1. Rajkumar SV. Novel approaches to the management of myeloma. Oncology (Williston Park) 2005; 19: 621-625.
2. Russell SJ. Replicating vectors for cancer therapy: A question of strategy. Semin Cancer Biol 1994; 5: 437-443.
3. Thorne SH, Hermiston T, Kirn D. Oncolytic virotherapy: Approaches to tumor targeting and enhancing antitumor effects. Semin Oncol 2005; 32: 537-548.
4. Nakamura T, Russell SJ. Oncolytic measles viruses for cancer therapy. Expert Opin Biol Ther 2004; 4: 1685-1692.
5. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD et al. Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 2005; 23: 209-214.
6. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. Noninvasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 2002; 8: 527-531.
7. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103: 1641-1646.
8. Peng KW, Ahmann GJ, Pham L, Greipp PR, Cattaneo R, Russell SJ. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001; 98: 2002-2007.
9. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002; 62: 4656-4662.
10. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003; 63: 2462-2469.
11. Dingli D, Peng KW, Harvey ME, Vongpunsawad S, Bergert ER, Kyle RA et al. Interaction of measles virus vectors with Auger electron emitting radioisotopes. Biochem Biophys Res Commun 2005; 337: 22-29.
12. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Therapy 2001; 8: 341-348.
13. Croyle MA, Chirmule N, Zhang Y, Wilson JM. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 2002; 13: 1887-1900.
14. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006; 311: 1780-1784.
15. Harrington K, Alvarez-Vallina L, Crittenden M, Gough M, Chong H, Diaz RM et al. Cells as vehicles for cancer gene therapy: The missing link between targeted vectors and systemic delivery? Hum Gene Ther 2002; 13: 1263-1280.
16. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
17. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 1997; 3: 1354-1361.
18. Coukos G, Makrigiannakis A, Kang EH, Caparelli D, Benjamin I, Kaiser LR et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 1999; 5: 1523-1537.
19. Raykov Z, Balboni G, Aprahamian M, Rommelaere J. Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer 2004; 109: 742-749.
20. Jevremovic D, Gulati R, Hennig I, Diaz RM, Cole C, Kleppe L et al. Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors. Am J Physiol Heart Circ Physiol 2004; 287: H494-H500.
21. Garcia-Castro J, Martinez-Palacio J, Lillo R, Garcia-Sanchez F, Alemany R, Madero L et al. Tumor cells as cellular vehicles to deliver gene therapies to metastatic tumors. Cancer Gene Ther 2005; 12: 341-349.
22. Cole C, Qiao J, Kottke T, Diaz RM, Ahmed A, Sanchez-Perez L et al. Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med 2005; 11: 1073-1081.
23. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006; 5: 755-766.
24. Griffin D. Measles virus. In: Knipe D, Howley P, Griffin D, Lamb R, Martin M, Roizman B, Strauss S (eds). Field's Virology. Lippincott Williams & Wilkins: Philadelphia, 2001, pp 1401.
25. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666-675.
26. Riviere I, Sadelain M, Brentjens RJ. Novel strategies for cancer therapy: The potential of genetically modified T lymphocytes. Curr Hematol Rep 2004; 3: 290-297.
27. Ratnam S, Gadag V, West R, Burris J, Oates E, Stead F et al. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J Clin Microbiol 1995; 33: 811-815.
28. Shih IM, Torrance C, Sokoll LJ, Chan DW, Kinzler KW, Vogelstein B. Assessing tumors in living animals through measurement of urinary beta-human chorionic gonadotropin. Nat Med 2000; 6: 711-714.
29. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR et al. Measles antibody: Reevaluation of protective titers. J Infect Dis 1990; 162: 1036-1042.
30. Watts A, Foley A, Awwad M, Treter S, Lambrigts D, Buhler L et al. Plasma perfusion by apheresis through a gal immunoaffinity column successfully depletes anti-Gal antibody: experience with 275 aphereses in baboons. Transplant Proc 2000; 32: 860.
31. Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 2000; 82: 1261-1265.
32. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61: 4750-4755.
33. Nanan R, Chittka B, Hadam M, Kreth HW. Measles virus infection causes transient depletion of activated T cells from peripheral circulation. J Clin Virol 1999; 12: 201-210.
34. Gough M, Crittenden M, Thanarajasingam U, Sanchez-Perez L, Thompson J, Jevremovic D et al. Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. J Immunol 2005; 174: 5766-5773.
35. Kershaw MH, Teng MW, Smyth MJ, Darcy PK. Supernatural T cells: Genetic modification of T cells for cancer therapy. Nat Rev Immunol 2005; 5: 928-940.
36. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000; 406: 893-897.
37. Ong HT, Timm MM, Greipp PR, Witzig TE, Dispenzieri A, Russell SJ et al. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol 2006; 34: 713-720.